Expression and underlying roles of IGFBP-3 in paclitaxel-treated gastric cancer Sgc-7901 cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5741-5745

  Huang, Gang ^a   Dang, Zhong Feng ^b   Dang, Ya Mei ^a   Cai, Wei ^a   Li, Yuan ^a   Chen, Yi Rong ^a   Xie, Xiao Dong ^a  

^a LANZHOU UNIVERSITY   (China)

^b Tumor Hospital of Gansu Province   (China)

Author keywords

Apoptosis; Gastric cancer; IGFBPs; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; IGFBP-2 PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN; MESSENGER RNA; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; TUBULIN MODULATOR;

APOPTOSIS; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; RNA INTERFERENCE; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TUBULIN MODULATORS;

EID: 84905985809     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5741     Document Type: Article

References (23)

1. Adams JM, S Cory (1998). The Bcl-2 protein family: arbiters of cell survival. Science, 281, 1322-6
2. Alami N, V Page, Q Yu, et al (2008). Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res, 18, 487-96
3. Biernacka KM, CC Uzoh, L Zeng, et al (2013). Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer, 20, 741-51
4. Cortes-Sempere M, MP de Miguel, O Pernia, et al (2013). IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/ Akt pathway in non-small cell lung cancer. Oncogene, 32, 1274-83
5. Dang YM, Huang G, Chen YR, et al (2014). Sulforaphane inhibits the proliferation of the BIU87 bladder cancer cell line via IGFBP-3 elevation. Asian Pac J Cancer Prev. 15, 1517-20
6. Duggan C, CY Wang, ML Neuhouser, et al (2013). Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer, 132, 1191-200
7. Eichhorn JM, SE Alford, N Sakurikar, et al (2014). Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Exp Cell Res, 322, 415-24
8. Foulstone EJ, L Zeng, CM Perks, et al (2013). Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology, 154, 1780-93
9. Holdaway IM, BH Mason, AE Lethaby, et al (2003). Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg, 73, 905-8
10. Hossein G, Keshavarz M, Ahmadi S, et al (2012). Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev, 14, 7561-8
11. Liang PI, YH Wang, TF Wu, et al (2013). IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol, 66, 573-82
12. Kiyoshima T, H Yoshida, H Wada, et al (2013). Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS One, 8, 80998
13. Koyama S, LJ Cobb, HH Mehta, et al (2010). Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res, 20, 55-62
14. Kalluri HS, RJ Dempsey (2011). IGFBP-3 inhibits the proliferation of neural progenitor cells. Neurochem Res, 36, 406-11
15. Williams AC, H Smartt, HZ AM, et al (2007). Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ, 14, 137-45
16. Peters I, I Tossidou, J Achenbach, et al (2006). IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol, 17, 1644-56
17. Soubry A, D Il'yasova, R Sedjo, et al (2012). Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. Int J Cancer, 131, 512-7
18. Sunderic M, B Dukanovic, V Malenkovic, et al (2014). Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. Exp Mol Pathol, 96, 48-53
19. Vallon M, C Seidl, B Blechert, et al (2012). Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest. Eur J Nucl Med Mol Imaging, 39, 1886-97
20. Kang WK, I Lee, U Ko, et al (2005). Differential effects of RhoA signaling on anticancer agent-induced cell death. Oncol Rep, 13, 299-304
21. Wang X, JJ Beitler, H Wang, et al (2014). Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One, 9, 86369
22. Zhang GJ, Z Zhang (2013). Effect of Bcl-2 on apoptosis and transcription factor NF-kappaB activation induced by adriamycin in bladder carcinoma BIU87 cells. Asian Pac J Cancer Prev, 14, 2387-91
23. Zeng L, C Jarrett, K Brown, et al (2013). Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells. Exp Cell Res, 319, 2282-95.